Zacks Investment Research on MSN
IRWD rises 307% in 6 months: Is this an indication to buy the stock?
Shares of Ironwood Pharmaceuticals IRWD have risen sharply over the past six months, primarily driven by the improving demand for its sole marketed product, Linzess (linaclotide) and the company’s ...
Many Medicare Part D plans cover Linzess, but out-of-pocket costs can vary because private insurance companies manage these plans. Linzess is an expensive medication with no generic alternatives ...
– Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% ...
Ironwood Pharmaceuticals IRWD has been witnessing improved demand for its sole marketed product, Linzess (linaclotide), in recent quarters. The company markets Linzess in the United States in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results